ALLO
HEALTHCAREAllogene Therapeutics Inc
AI Insight
What's Moving ALLO Today?
No stock-specific AI insight has been generated for ALLO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.98$4.46
$2.05
Fundamentals
Market Cap$714M
P/E Ratio—
EPS$-0.77
Dividend Yield—
Dividend / Share—
ROE-52.3%
Profit Margin—
Debt / Equity—
Trading
Volume9.6M
Avg Volume (10D)—
Shares Outstanding345.2M
ALLO News
22 articles- How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune DiseaseYahoo Finance·Jun 17, 2026
- Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?Yahoo Finance·Jun 12, 2026
- Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell PortfolioYahoo Finance·Jun 7, 2026
- Allogene Therapeutics Announces Planned CEO SuccessionYahoo Finance·May 28, 2026
- Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesYahoo Finance·May 26, 2026
- Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1Yahoo Finance·May 14, 2026
- Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders247 Wall St·May 14, 2026
- Allogene Therapeutics Q1 Net Loss NarrowsMoomoo·May 14, 2026
- Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...Yahoo Finance·May 14, 2026
- Allogene Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 14, 2026
- Allogene Therapeutics Q1 2026 Earnings Call TranscriptYahoo Finance·May 13, 2026
- Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business UpdateYahoo Finance·May 13, 2026
- Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateYahoo Finance·May 6, 2026
- William Blair Initiates Natera (NTRA) With OutperformYahoo Finance·May 2, 2026
- Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common StockYahoo Finance·May 1, 2026
- Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest InYahoo Finance·Apr 25, 2026
- H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)Yahoo Finance·Apr 23, 2026
- Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and AustraliaYahoo Finance·Apr 21, 2026
- Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026Yahoo Finance·Apr 20, 2026
- Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common StockYahoo Finance·Apr 16, 2026
- Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed?Yahoo Finance·Apr 15, 2026
- Allogene Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire Inc.·Apr 15, 2026
All 22 articles loaded
Price Data
Open$2.08
Previous Close$2.07
Day High$2.12
Day Low$2.04
52 Week High$4.46
52 Week Low$0.98
52-Week Range
$0.98$4.46
$2.05
Fundamentals
Market Cap$714M
P/E Ratio—
EPS$-0.77
Dividend Yield—
Dividend / Share—
ROE-52.3%
Profit Margin—
Debt / Equity—
Trading
Volume9.6M
Avg Volume (10D)—
Shares Outstanding345.2M
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—